Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study

Study limitation reported by the research below: “The 'practice changing' flag is applied cautiously: PFS improvement is statistically significant, but confirmed OS benefit is absent at this interim analysis.”